Fridays Review: Compounded GLP-1 Quality and Clinical Pathways

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This is an independent PlexusDx review of Fridays (Fridays Health), a telehealth GLP-1 program that pairs a virtual clinical evaluation with compounded semaglutide and tirzepatide dispensed through licensed 503A pharmacies. As GLP-1 medications grow in popularity for weight management and metabolic health, consumers increasingly compare telehealth programs on pricing, pharmacy credentials, provider access, and support. This review explains how Fridays' program is structured and how it compares with the PlexusDx approach. PlexusDx is not affiliated with Fridays.

Full head-to-head: PlexusDx vs Fridays →

Fridays matters here because the compounded GLP-1 telehealth market lacks the unified regulatory oversight that applies to branded medications. Understanding what Fridays offers, how its pricing is labeled, and what clinical evidence supports compounded GLP-1 therapy can guide your conversation with healthcare providers. PlexusDx's approach emphasizes 503A-licensed pharmacy partnerships and optional genetic testing to support individualized treatment planning.

What Fridays Offers as a GLP-1 Telehealth Program

Fridays provides an online intake, a licensed-provider evaluation, and, where eligible, a prescription for compounded semaglutide or tirzepatide fulfilled by a 503A compounding pharmacy. The program bundles medication, shipping, and ongoing telehealth follow-up, and includes coaching and dietitian support. Fridays charges $0 membership and ships free (checkout line item, verified 2026-07-20).

Because Fridays dispenses compounded rather than FDA-approved branded medications, its formulations fall under state pharmacy board jurisdiction and USP standards rather than FDA approval. Evaluating any compounded GLP-1 program means checking pharmacy licensing (503A), quality-control practices, ingredient sourcing, transparent pricing, and provider support.

Fridays Pricing: Advertised Month-to-Month vs. Prepaid Bundles

Every Fridays price should carry a label, a date, and the surface it came from, because Fridays' rates moved materially within a single day. The grid below reflects Fridays' own pricing page as captured on 2026-07-20, alongside the PlexusDx month-to-month lead prices.

Item	Fridays	PlexusDx
Compounded semaglutide	$249/mo advertised month-to-month (joinfridays.com/pricing, 2026-07-20)	$189/mo month-to-month
Compounded tirzepatide	$359/mo advertised month-to-month (joinfridays.com/pricing, 2026-07-20)	$289/mo month-to-month
Prepaid multi-month	Lower per-month equivalent (a paid-annually plan works out to roughly $150/mo semaglutide, $240/mo tirzepatide)	Month-to-month lead; optional multi-month plans
Membership	$0	$0, no insurance required
Support	Coaching and dietitian support	Provider coordination plus optional Precision Peptide Genetic Test

PlexusDx's month-to-month rates run roughly $60–$70/mo below Fridays' advertised month-to-month for both compounds. Fridays also offers prepaid multi-month bundles, and it includes coaching and dietitian support—both real advantages worth weighing.

Compounded Semaglutide vs. Tirzepatide: Clinical Context

Compounded semaglutide targets GLP-1 receptors alone, while tirzepatide engages both GLP-1 and GIP receptors. Tirzepatide typically requires more rigorous quality controls due to dual-ingredient stability, so ask any compounded program—Fridays included—for lab data supporting stability and storage conditions that preserve potency.

PlexusDx offers both compounded semaglutide (starting $189/month) and tirzepatide (starting $289/month) through verified 503A pharmacies, with optional genetic testing to help identify which pathway may align better with individual metabolic profiles.

How Compounded GLP-1 Differs from FDA-Approved Options

The FDA regulates branded GLP-1 drugs (Ozempic, Wegovy, Mounjaro) through rigorous efficacy and safety trials, but compounded medications—like those Fridays and PlexusDx dispense—fall under state pharmacy board jurisdiction and USP standards. Compounded semaglutide and tirzepatide have clinical literature supporting their use, yet individual compounded formulations are not formally approved by the FDA.

When comparing programs, weigh pharmacy licensing, pricing transparency, and provider support rather than assuming any compounded product carries FDA-approved efficacy data. Both Fridays and PlexusDx rely on licensed 503A pharmacies for this oversight.

Safety Considerations and Program Transparency

Common GLP-1 side effects include nausea, vomiting, constipation, and rare pancreatitis risk. A transparent program discloses these risks, provides patient education, and maintains clear escalation protocols for serious adverse events. Before starting any compounded GLP-1 therapy, confirm your chosen program uses licensed 503A pharmacies, documents safety protocols, and offers provider support lines.

Ask your healthcare provider whether they have experience with the specific compounder involved. PlexusDx coordinates with licensed 503A pharmacies that maintain adverse-event logs and quality oversight.

How PlexusDx Supports a More Personalized Approach

PlexusDx's commitment to 503A-licensed compounding pharmacies means every semaglutide and tirzepatide formulation undergoes state pharmacy board oversight and USP <797> standards. While this does not replace FDA approval, it ensures manufacturing transparency and accountability.

The Precision Peptide Genetic Test offers an additional layer of personalization. By examining genetic predispositions in peptide-signaling pathways (GIPR rs1800437, FTO rs9939609, MC4R rs17782313), PlexusDx helps you and your provider move beyond generic GLP-1 recommendations. Genetic insights may support discussions about whether compounded semaglutide, tirzepatide, or dual-compound formulas align with your metabolic architecture.

Your next step: confirm your chosen program's 503A licensing, discuss genetic predispositions with your provider, and request a consultation with PlexusDx's team to explore which compounded formulation and starting protocol may fit your health goals and medical history.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What does this Fridays review cover?

This independent PlexusDx review examines Fridays as a telehealth GLP-1 program: its compounded semaglutide and tirzepatide, 503A pharmacy fulfillment, advertised month-to-month pricing ($249/mo semaglutide and $359/mo tirzepatide as of 2026-07-20), $0 membership, and coaching support—compared with the PlexusDx approach.

Are Fridays' compounded medications FDA-approved?

No. Fridays dispenses compounded semaglutide and tirzepatide, which follow state pharmacy rules and USP standards rather than FDA approval. The FDA approves branded medications through clinical trials; compounded formulations are prepared by licensed 503A pharmacies.

How does PlexusDx compare to Fridays?

PlexusDx and Fridays both dispense compounded GLP-1 through licensed 503A pharmacies. PlexusDx leads with month-to-month pricing ($189 semaglutide / $289 tirzepatide)—about $60–$70/mo below Fridays' advertised month-to-month—and adds optional genetic testing ($298), while Fridays' prepaid multi-month bundles can cost less per month and include coaching.

Should I choose a GLP-1 program on price alone?

No. Price and program features matter, but your healthcare provider should evaluate your medical eligibility, medication interactions, and contraindications before you enroll in Fridays, PlexusDx, or any GLP-1 program.

Can genetic testing improve my GLP-1 outcomes?

Genetic predispositions in peptide pathways may inform personalized dosing or formulation choices when discussed with your provider—but do not guarantee outcomes.

Related Reading

• Fridays Zepbound
• Fridays Peptides
• Fridays Coupon
• Fridays Ozempic

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.